Pomalyst, Imnovid (previously pomalidomide celgene)(pomalidomide)
Imnovid, Pomalidomide, Pomalyst (pomalidomide) is a small molecule pharmaceutical. Pomalidomide was first approved as Pomalyst on 2013-02-08. It is used to treat kaposi sarcoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Pomalyst (discontinued: Pomalidomide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pomalidomide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| POMALYST | Bristol Myers Squibb | N-204026 RX | 2013-02-08 | 4 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pomalidomide | ANDA | 2025-11-24 |
| pomalyst | New Drug Application | 2025-02-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
POMALIDOMIDE, POMALYST, BRISTOL | |||
| 2027-11-14 | PED | ||
| 2027-05-14 | ODE-296, ODE-297 | ||
| 2024-05-20 | PED | ||
| 2023-11-20 | M-14 | ||
HCPCS
No data
Clinical
Clinical Trials
318 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 87 | 130 | 44 | 3 | 20 | 241 |
| Plasma cell neoplasms | D054219 | — | — | 52 | 70 | 24 | 3 | 16 | 137 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 8 | 15 | 7 | — | 1 | 27 |
| Neoplasms | D009369 | — | C80 | 10 | 8 | 2 | — | — | 16 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 3 | 4 | 1 | — | — | 6 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | 4 | 1 | — | — | 5 |
| Plasmacytoma | D010954 | — | C90.3 | — | 2 | 1 | — | — | 3 |
| Polycythemia vera | D011087 | — | D45 | 1 | 2 | 1 | — | — | 3 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | 2 | 1 | — | — | 3 |
| Blood protein disorders | D001796 | — | — | 1 | 2 | 1 | — | — | 3 |
| Paraproteinemias | D010265 | — | D47.2 | 1 | 2 | 1 | — | — | 3 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyloidosis | D000686 | EFO_1001875 | E85 | 4 | 10 | — | — | 1 | 12 |
| Lymphoma | D008223 | — | C85.9 | 7 | 8 | — | — | — | 12 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 4 | — | — | 3 | 11 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 4 | 7 | — | — | 1 | 10 |
| B-cell lymphoma | D016393 | — | — | 4 | 3 | — | — | 1 | 7 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 3 | — | — | — | 6 |
| Kaposi sarcoma | D012514 | — | C46 | 3 | 3 | — | — | — | 5 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 3 | — | — | — | 5 |
| Leukemia | D007938 | — | C95 | 1 | 3 | — | — | — | 4 |
| Hematologic neoplasms | D019337 | — | — | 3 | 3 | — | — | — | 4 |
Show 50 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 4 | — | — | — | — | 4 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Intraocular lymphoma | D064090 | — | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Neurofibromatosis 1 | D009456 | — | Q85.01 | 1 | — | — | — | — | 1 |
| Neurofibromatoses | D017253 | — | Q85.00 | 1 | — | — | — | — | 1 |
| Pathologic dilatation | D004108 | — | — | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pomalidomide |
| INN | pomalidomide |
| Description | Pomalidomide is an aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. It has a role as an antineoplastic agent, an immunomodulator and an angiogenesis inhibitor. It is a dicarboximide, a member of isoindoles, a member of piperidones and an aromatic amine. It is functionally related to a thalidomide. |
| Classification | Small molecule |
| Drug class | thalidomide derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O |
Identifiers
| PDB | — |
| CAS-ID | 19171-19-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL43452 |
| ChEBI ID | 72690 |
| PubChem CID | 134780 |
| DrugBank | DB08910 |
| UNII ID | D2UX06XLB5 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Pomalyst – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Pomalyst – Celgene
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,760 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pomalidomide, Pomalyst
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
93,837 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use